16:00 EDT Aravive trading halted, news pending
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARAV:
- Aravive (NASDAQ:ARAV) Plummets On Phase 3 Disappointment In Ovarian Cancer
- Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023
- Aravive management to meet virtually with Cantor Fitzgerald
- Aravive to Participate in William Blair’s Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023
- Aravive price target lowered to $9 from $12 at BTIG